SMARCB1 and mature T-cell and NK-cell non-Hodgkin lymphoma: While the molecular origin of the loss of SMARCB1 in the human PTCL might be heterogeneous, including single nucleotide and structural genomic variants as well as probably epigenomic changes, we were able to model the disease phenotype in a targeted mouse model by inactivating Smarcb1 in mature T-cells.